Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) (BEYOND)
Type 2 Diabetes

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring type 2 diabetes, GLP-1RA, SGLT-2i, basal insulin, basal bolus, glycemic control
Eligibility Criteria
Inclusion Criteria:
- Poor glycemic control (HbA1c ≥7.5%)
- Stable basal bolus insulin regimen for almost a year, eventually associated with metformin.
Exclusion Criteria:
- Type 1 diabetes or secondary diabetes;
- Previous treatment for the last three months with GLP-1RA or DPP-4 inhibitors;
- Hypersensitivity towards active substances or other ingredients of the drugs used in the study
- Participation in other trial with experimental drugs within 30 days
- Diseases that represent contraindication to GLP-1RA use (pancreatitis, gallstones)
- Pregnancy or planned pregnancy within the time of the study
- Serum creatinine > 1,3 mg/dL in women and >1,4 mg/dL in men
- eGFR < 30 mL/min
- Previous cancer or antineoplastic therapy for five years before randomization
- Current therapy with glucocorticoid (oral, topic or sistemic administration) or with antypsichotic drugs
- Previous ketoacidosis
- Any clinical, psychologic or psychiatric condition that is incompatible with the study according to the investigator
Sites / Locations
- Unit of Endocrinology and Metabolic Diseases
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
FR insulin/GLP-1RA
Insulin/SGLT-2i
Basal Bolus
Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi
Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.
Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals